318 In the index

Bimagrumab BYM338

An antibody drug that blocks a muscle-limiting signal in the body, encouraging muscle growth. Human trials in older adults and people with obesity show it builds muscle, and when paired with a weight-loss drug it helped people lose fat while keeping more muscle, though it's still not an approved medication.

Also known as BYM-338

Effects Build muscle Lose fat

Routes Injectable

Legal status Unapproved / investigational

WADA Banned at all times

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not approved; trial dosing under evaluation

Reported range Phase II trials: roughly 10 mg/kg IV every 4 weeks, alone or with semaglutide

Route Intravenous infusion

Frequency Every 4 weeks (trial protocol)

Duration Trial durations of several months

Investigational myostatin/activin-pathway antibody; recent trials paired it with semaglutide for fat loss with muscle preservation. Not an approved product.

Where this comes from Published Phase II clinical trial data (Versanis/Eli Lilly)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.